Journal Article

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Giladi, Michael, Karthaus, Meinolf, Ullmann, Andrew J, Schmitt-Hoffmann, Anne-Hortense, Rahav, Galia, Cornely, Oliver A, Lee, Misun, Patterson, Thomas F, Neofytos, Dionysios, Lortholary, Olivier, Kontoyiannis, Dimitrios P, Selleslag, Dominik, Herbrecht, Raoul, Maher, Rochelle M, Bow, Eric J, Shoham, Shmuel, Lee, Dong-Gun, Thompson, George R, Marr, Kieren A, Aoun, Mickael, Hope, William, Morrison, Vicki A, Maertens, Johan A, Raad, Issam I, Heinz, Werner J, Zeiher, Bernhardt, Oren, Ilana, Baddley, John W

2016

Overview

Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1:1 ratio using an interactive voice–web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of −1·0% (95% CI −7·8 to 5·7). Because the upper bound of the 95% CI (5·7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0·122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0·016), eye disorders (39 [15%] vs 69 [27%]; p=0·002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0·037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p<0·001). Isavuconazole was non-inferior to voriconazole for the primary treatment of suspected invasive mould disease. Isavuconazole was well tolerated compared with voriconazole, with fewer study-drug-related adverse events. Our results support the use of isavuconazole for the primary treatment of patients with invasive mould disease. Astellas Pharma Global Development, Basilea Pharmaceutica International.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Administration, Oral / Adult / Aged / Antifungal Agents - administration & dosage / Antifungal Agents - adverse effects / Antifungal Agents - therapeutic use / Aspergillosis - drug therapy / Aspergillosis - mortality / Aspergillus / Clinical trials / Double-Blind Method / Drug Administration Schedule / Drug therapy / Female / Fungal infections / Fungi / Hematology / Humans / Injections, Intravenous / Internal Medicine / Male / Middle Aged / Mortality / Mycoses - drug therapy / Mycoses - mortality / Nitriles - administration & dosage / Nitriles - adverse effects / Nitriles - therapeutic use / Pyridines - administration & dosage / Pyridines - adverse effects / Pyridines - therapeutic use / Stem cells / Studies / Transplants & implants / Treatment Outcome / Triazoles - administration & dosage / Triazoles - adverse effects / Triazoles - therapeutic use / Voriconazole - administration & dosage / Voriconazole - adverse effects / Voriconazole - therapeutic use